glp-1 alcohol abuse Semaglutide for weight loss was linked to a sharp drop in use in this case report GLP-1 medications: The next big

Findings The researchers did not detect semaglutide in milk samples collected 0, 12, and 24 after drug administration

It names women with normal metabolic status, eating disorders, or severe gastrointestinal symptoms as potentially unsuitable, in contrast to those with documented metabolic dysfunction, insulin resistance, or overweight and obesity

This question has gained attention as GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) become increasingly prescribed for type 2 diabetes and weight management

Methods: We performed a retrospective cohort study, using data from UNOS, of patients who underwent first Re-LT between 2022-2023 and who were re-transplanted at centers that utilized MP preservation techniques